Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5498052 | 0.77 | CA1 (0.55) | CA1CA2ESR2MAPTSMN1; SMN2 | |
| SCHEMBL13498610 | 0.77 | CA1 (0.55) | CA1CA2ESR2MAPTSMN1; SMN2 | |
| SCHEMBL17233757 | 0.75 | CA1 (0.51) | CA1CA2ESR2MAPTSMN1; SMN2 | |
| SCHEMBL18461191 | 0.75 | SMN1; SMN2 (0.54) | CA1CA2ESR2MAPTSMN1; SMN2 | |
| SCHEMBL7991911 | 0.74 | SMN1; SMN2 (0.48) | CA1CA2ESR2MAPTSMN1; SMN2 | |
| SCHEMBL7994325 | 0.74 | SMN1; SMN2 (0.48) | CA1CA2ESR2MAPTSMN1; SMN2 | |
| SCHEMBL7979731 | 0.74 | SMN1; SMN2 (0.51) | CA1CA2ESR2MAPTSMN1; SMN2 | |
| SCHEMBL7997324 | 0.74 | SMN1; SMN2 (0.51) | CA1CA2ESR2MAPTSMN1; SMN2 | |
| SCHEMBL13286850 | 0.73 | PPM1B (0.56) | ALDH1A1NPC1CES2 | |
| SCHEMBL11985689 | 0.72 | MAPT (0.73) | GSK3BCA1CA2ESR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2181986-B1 | Process for the preparation of a precursor of montelukast | SYNTHON BV (NL) | 2011-10-19 | — | — | EP | disclosed |
| US-7501517-B2 | Process for making montelukast and intermediates therefor | SYNTHON IP, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20050245569-A1 | Process for making montelukast and intermediates therefor | SYNTHON IP INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245569-A1 | Process for making montelukast and intermediates therefor | LTA4H, CYP4A11, LTC4S | GSK3B 2400/4885CA1 3566/4885CA2 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.